Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study-Reference-Cited by-同舟云学术

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study

Published:2014-01 Issue:1 Volume:50 Page:170-177
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Di Giannatale Angela,Dias-Gastellier Nathalie,Devos Annick,Mc Hugh Kieran,Boubaker Ariane,Courbon Frederic,Verschuur Arnaud,Ducassoul Stéphane,Malekzadeh Katty,Casanova Michela,Amoroso Loredana,Chastagner Pascal,Zwaan Christian M.,Munzer Caroline,Aerts Isabelle,Landman-Parker Judith,Riccardi Riccardo,Le Deley Marie-Cecile,Geoerger Birgit,Rubie Hervé

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Neuroblastoma;Maris;Lancet,2007

2. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project;London;J Clin Oncol,2011

3. Antitumor imidazotetrazines – XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones;Tisdale;Biochem Pharmacol,1987

4. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models;Middlemas;Clin Cancer Res,2000

5. Temozolomide: a milestone in neuro-oncology and beyond?;Mutter;Expert Rev Anticancer Ther,2006

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial;Journal of Clinical Oncology;2024-04-01

2. Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series;Scientific Reports;2023-11-07

3. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma;Journal for ImmunoTherapy of Cancer;2023-09

4. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience;Frontiers in Oncology;2022-12-23

5. Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry;Current Oncology;2022-10-30